RVNC logo

Revance Therapeutics (RVNC) Cash From Investing

Annual CFI

$109.74 M
+$248.54 M+179.06%

December 31, 2023

Summary

Performance

1-Year Change

+179.06%

3-Year Change

+804.62%

5-Year Change

+202.54%

15-Year Change

-7.62%

RVNC Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

94.35%
RVNC annual cash flow from investing activities is higher than 94.35% of companies in Healthcare sector

High & Low

All-time High

$118.79 M
RVNC annual cash flow from investing activities is currently -7.62% below its historical high of $118.79 million

3-Year Low

-$138.80 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
RVNC previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
RVNC next annual earnings announcement is scheduled for Feb 28, 2025

OtherRVNCcash flowmetrics:

Annual CFF

$136.57 M
RVNC annual cash flow from financing activities is $136.57 million

Annual CFO

-$216.57 M
RVNC annual cash flow from operations is -$216.57 million

Annual FCF

-$223.46 M
RVNC annual free cash flow is -$223.46 million

Annual CAPEX

$6.89 M
RVNC annual capital expenditures is $6.89 million

Quarterly CFI

$23.29 M
+$30.18 M+438.12%

September 30, 2024

Summary

Performance

3-Month Change

+438.12%

1-Year Change

-54.85%

3-Year Change

+38.59%

5-Year Change

+2437.36%

RVNC Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

90.03%
RVNC quarterly cash flow from investing activities is higher than 90.03% of companies in Healthcare sector

High & Low

All-time High

$96.30 M
RVNC quarterly cash flow from investing activities is currently -75.81% below its historical high of $96.30 million

3-Year Low

-$118.44 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RVNC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
RVNC next earnings announcement is scheduled for Feb 28, 2025

OtherRVNCcash flowmetrics:

Quarterly CFF

-$6.09 M
RVNC quarterly cash flow from financing activities is -$6.09 million

Quarterly CFO

-$41.09 M
RVNC quarterly cash flow from operations is -$41.09 million

Quarterly FCF

-$41.15 M
RVNC quarterly free cash flow is -$41.15 million

Quarterly CAPEX

$61.00 K
RVNC quarterly capital expenditures is $61.00 thousand

TTM CFI

-$12.94 M
-$28.29 M-184.22%

September 30, 2024

Summary

Performance

3-Month Change

-184.22%

1-Year Change

-108.72%

3-Year Change

+80.4%

5-Year Change

+26.47%

RVNC TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

31.2%
RVNC TTM cash flow from investing activities is higher than 31.2% of companies in Healthcare sector

High & Low

All-time High

$148.33 M
RVNC TTM cash flow from investing activities is currently -108.72% below its historical high of $148.33 million

3-Year Low

-$152.12 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RVNC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
RVNC next earnings announcement is scheduled for Feb 28, 2025

OtherRVNCcash flowmetrics:

TTM CFF

$81.70 M
RVNC TTM cash flow from financing activities is $81.70 million

TTM CFO

-$190.89 M
RVNC TTM cash flow from operations is -$190.89 million

TTM FCF

-$194.91 M
RVNC TTM free cash flow is -$194.91 million

TTM CAPEX

$4.02 M
RVNC TTM capital expenditures is $4.02 million

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

RVNC Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+179.1%-54.9%-108.7%
3 y3 years+804.6%+38.6%+80.4%
5 y5 years+202.5%+2437.4%+26.5%

RVNC Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+179.1%-75.6%+119.7%-108.7%+91.5%
5 y5-yearat high+179.1%-75.6%+119.7%-108.7%+91.5%
alltimeall time-7.6%+179.1%-75.8%+111.6%-108.7%+93.5%

Revance Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2024
-
$23.29 M(-438.1%)
-$12.94 M(-184.2%)
Jun 2024
-
-$6.89 M(-78.3%)
$15.36 M(-188.9%)
Mar 2024
-
-$31.71 M(-1437.9%)
-$17.29 M(-115.8%)
Dec 2023
$109.74 M(-179.1%)
$2.37 M(-95.4%)
$109.74 M(-26.0%)
Sep 2023
-
$51.59 M(-230.5%)
$148.33 M(-783.5%)
Jun 2023
-
-$39.53 M(-141.5%)
-$21.70 M(-75.4%)
Mar 2023
-
$95.32 M(+132.7%)
-$88.05 M(-36.6%)
Dec 2022
-$138.80 M(+367.9%)
$40.96 M(-134.6%)
-$138.80 M(-8.8%)
Sep 2022
-
-$118.44 M(+11.9%)
-$152.12 M(+802.0%)
Jun 2022
-
-$105.88 M(-337.6%)
-$16.86 M(-131.6%)
Mar 2022
-
$44.57 M(+61.2%)
$53.32 M(-279.8%)
Dec 2021
-$29.66 M(-344.5%)
$27.64 M(+64.5%)
-$29.66 M(-55.1%)
Sep 2021
-
$16.81 M(-147.1%)
-$66.00 M(+31.2%)
Jun 2021
-
-$35.69 M(-7.1%)
-$50.31 M(-163.5%)
Mar 2021
-
-$38.42 M(+342.1%)
$79.28 M(+553.5%)
Dec 2020
$12.13 M(-169.0%)
-$8.69 M(-126.7%)
$12.13 M(-76.6%)
Sep 2020
-
$32.50 M(-65.4%)
$51.74 M(+156.6%)
Jun 2020
-
$93.89 M(-188.9%)
$20.16 M(-202.2%)
Mar 2020
-
-$105.57 M(-441.4%)
-$19.72 M(+12.1%)
Dec 2019
-$17.59 M(-83.6%)
$30.92 M(+3268.1%)
-$17.59 M(-266.1%)
Sep 2019
-
$918.00 K(-98.3%)
$10.59 M(-73.5%)
Jun 2019
-
$54.01 M(-152.2%)
$40.03 M(-494.4%)
Mar 2019
-
-$103.44 M(-275.0%)
-$10.15 M(-90.5%)
Dec 2018
-$107.03 M
$59.10 M(+94.7%)
-$107.03 M(+53.3%)
DateAnnualQuarterlyTTM
Sep 2018
-
$30.36 M(+692.2%)
-$69.83 M(-18.5%)
Jun 2018
-
$3.83 M(-101.9%)
-$85.71 M(+61.9%)
Mar 2018
-
-$200.32 M(-308.0%)
-$52.95 M(-144.6%)
Dec 2017
$118.79 M(-257.3%)
$96.30 M(+565.5%)
$118.79 M(-491.4%)
Sep 2017
-
$14.47 M(-60.5%)
-$30.35 M(-163.2%)
Jun 2017
-
$36.59 M(-228.1%)
$48.02 M(+19.1%)
Mar 2017
-
-$28.57 M(-45.9%)
$40.32 M(-153.4%)
Dec 2016
-$75.50 M(+33.8%)
-$52.84 M(-156.9%)
-$75.50 M(+239.9%)
Sep 2016
-
$92.84 M(+221.3%)
-$22.21 M(-81.0%)
Jun 2016
-
$28.89 M(-120.0%)
-$116.62 M(-41.4%)
Mar 2016
-
-$144.39 M(<-9900.0%)
-$199.08 M(+252.9%)
Dec 2015
-$56.41 M(+708.8%)
$446.00 K(-128.4%)
-$56.41 M(-3.5%)
Sep 2015
-
-$1.57 M(-97.1%)
-$58.47 M(-0.8%)
Jun 2015
-
-$53.57 M(+3003.5%)
-$58.92 M(+656.3%)
Mar 2015
-
-$1.73 M(+7.5%)
-$7.79 M(+11.7%)
Dec 2014
-$6.97 M(+9.0%)
-$1.61 M(-20.7%)
-$6.97 M(-24.0%)
Sep 2014
-
-$2.03 M(-16.7%)
-$9.17 M(+22.3%)
Jun 2014
-
-$2.43 M(+167.4%)
-$7.50 M(+6.2%)
Mar 2014
-
-$910.00 K(-76.1%)
-$7.06 M(+10.3%)
Dec 2013
-$6.40 M(+2523.8%)
-$3.81 M(+974.9%)
-$6.40 M(+146.5%)
Sep 2013
-
-$354.00 K(-82.2%)
-$2.60 M(+15.8%)
Jun 2013
-
-$1.99 M(+697.2%)
-$2.24 M(+797.2%)
Mar 2013
-
-$250.00 K
-$250.00 K
Dec 2012
-$244.00 K(+225.3%)
-
-
Dec 2011
-$75.00 K
-
-

FAQ

  • What is Revance Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Revance Therapeutics?
  • What is Revance Therapeutics annual CFI year-on-year change?
  • What is Revance Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Revance Therapeutics?
  • What is Revance Therapeutics quarterly CFI year-on-year change?
  • What is Revance Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Revance Therapeutics?
  • What is Revance Therapeutics TTM CFI year-on-year change?

What is Revance Therapeutics annual cash flow from investing activities?

The current annual CFI of RVNC is $109.74 M

What is the all time high annual CFI for Revance Therapeutics?

Revance Therapeutics all-time high annual cash flow from investing activities is $118.79 M

What is Revance Therapeutics annual CFI year-on-year change?

Over the past year, RVNC annual cash flow from investing activities has changed by +$248.54 M (+179.06%)

What is Revance Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of RVNC is $23.29 M

What is the all time high quarterly CFI for Revance Therapeutics?

Revance Therapeutics all-time high quarterly cash flow from investing activities is $96.30 M

What is Revance Therapeutics quarterly CFI year-on-year change?

Over the past year, RVNC quarterly cash flow from investing activities has changed by -$28.29 M (-54.85%)

What is Revance Therapeutics TTM cash flow from investing activities?

The current TTM CFI of RVNC is -$12.94 M

What is the all time high TTM CFI for Revance Therapeutics?

Revance Therapeutics all-time high TTM cash flow from investing activities is $148.33 M

What is Revance Therapeutics TTM CFI year-on-year change?

Over the past year, RVNC TTM cash flow from investing activities has changed by -$161.26 M (-108.72%)